Executive Director, Chairman, Chief Executive Officer and President
Mr. Parkinson has more than 30 years of experience in the biopharmaceutical industry. As co-founder and CEO of TranXenoGen, Mr. Parkinson oversaw its IPO and admission to AIM in July of 2000, increasing its market value from $90M to $250M within one year. As President and CEO of CereMedix, a drug discovery and development company, he advanced their first product to clinical trials. Mr. Parkinson has raised both public and private capital, built management teams, managed M&A, in-licensed and out-licensed products/technology, and secured major industry contracts and collaborations for a number of companies including Advanced Cell Technology where he was CEO, Johnson & Johnson, PPL Therapeutics, Genzyme Transgenics and Fermetech Ltd.
Steven A. Kates Ph.D.
Chief Scientific Officer, Vice President, Regulatory Affairs
Dr. Kates joined Lakewood-Amedex in May 2016. He is a highly experienced pharmaceutical executive with more than 25 years in R&D for both life science products and human therapeutics. Dr. Kates is regarded as a world-leading chemist and industry expert in peptide design and manufacturing in the biopharmaceutical industry. He has advanced several compounds through drug development from early pre-clinical to early clinical development. He was responsible for the successful development of clinical candidates for both 505(b)(2) and NCE applications. He has held senior positions at Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation and is a consultant to virtual and semi-virtual biotechnology companies.
Dr. Kates has written or co-authored more than 100 articles, reviews, and patents and is an ad hoc reviewer for the NIH bio-organic and natural products study section. He has served as editor of ADMET for Medicinal Chemists: A Practical Guide and Solid-Phase Synthesis: A Practical Guide; guest editor of Biopolymers; and as a member of the Editorial Board of International Journal of Peptide Research and Therapeutics. An Adjunct Professor of Chemistry at Northeastern University and Visiting Professor of Chemistry at Brandeis University, Dr. Kates earned his B.S. in Chemistry from Bates College, Ph.D. in Synthetic Organic Chemistry from Brandeis University and conducted post-doctoral studies at The Massachusetts Institute of Technology.
Dr. Patrick O’Connor, FRCP (Edin), Ph.D.
Chief Medical Officer
Dr. Patrick C. O’Connor has more than 30 years of pharmaceutical/device product development in the U.S., Europe and Japan. Dr. O’Connor graduated in medicine and after his internship he spent six years in Basic Physiology and Pharmacology research at University College, Cork, Ireland and Manchester University in the U.K. leading to a Ph.D. He worked for ten years in the British National Health Service at various academic centers. Dr. O’Connor is a registered specialist in the U.K., with accreditation in Internal Medicine and Clinical Pharmacology.
Since 2012 he has been Managing Director, Strategic Clinical Development for Auven Therapeutics, a hybrid private equity fund. Prior, he held senior positions at Boots Pharmaceuticals, Pharmaco, PPD, Ferring Group of Companies and Celtic Pharma. Over the course of his career Dr. O’Connor has been intimately involved in product development across a wide variety of therapeutic areas with particular emphasis on managing external vendors.
Peter F. Ceccacci, CPA
Mr. Ceccacci has over 35 years of experience which includes an extensive career in public accounting and more recently in industry with private companies. As a shareholder in public accounting for many years and most recently Executive VP of Finance, he has gained valuable experience in working with private businesses in various industries and in particular significant experience in healthcare and technology. Peter is an accomplished executive with comprehensive experience in accounting, finance, management, and information systems. Skilled in analytics, financial reporting, budgeting, and projection modeling, he brings a wealth of financial experience to the Company.